<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407196</url>
  </required_header>
  <id_info>
    <org_study_id>AZTRMT 2017-02</org_study_id>
    <nct_id>NCT03407196</nct_id>
  </id_info>
  <brief_title>Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey</brief_title>
  <acronym>DAPA-TURK</acronym>
  <official_title>Dapagliflozin in Type 2 Diabetes Patients in Routine Internal Medicine and Endocrinology Outpatient Clinical Care; a Retrospective Cohort Study From Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca Turkey</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optimum Contract Research Organization, Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca Turkey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background/Rationale:

      Objectives and Hypotheses: To describe characteristics of patients with type 2 diabetes (T2D)
      prescribed dapagliflozin in routine internal medicine and endocrinology outpatient clinical
      care in Turkey; to describe changes in HbA1c(%), weight(kg), BMI(kg/m^2) and blood pressure
      (BP)(mmHg) in these patients; and the discontinuation rates of dapagliflozin in the first 6
      months of treatment.

      Methods:

      Study design: a retrospective observational cohort study. Data Source(s): Patient medical
      records of 81 different centres. Study Population: patients with a diagnosis of T2D, a first
      prescription for dapagliflozin, between July 2016 and Aug 2017 and who have been registered
      in the participating centre at least 6 months prior to first prescription of dapagliflozin.

      Study variables: patient characteristics: age, gender, smoking status, co-morbidities,
      duration of diabetes, prescribed medicines, HbA1c(%), weight(kg), body mass index
      (BMI)(kg/m^2) and blood pressure (BP)(mmHg).

      Outcome(s): description of patient characteristics, HbA1c(%), weight(kg), BMI(kg/m^2) and
      BP(mmHg) at baseline and during use of dapagliflozin at first visit (2,3 or 4 months) and
      second visit (5 or 6 months).

      Sample Size Estimations:1500 patients Statistical Analysis: the baseline characteristics and
      follow up variables will be described using frequency and percentage distributions for
      categorical variables. Continuous and count variables will be described using mean (Â±
      standard deviation), median (quartiles) and 95% confidence intervals. Proportion of patients
      falling above/below certain weight(kg)/BMI(kg/m^2), HbA1c(%) and BP(mmHg) thresholds will be
      derived. HbA1c(%), weight(kg), BMI(kg/m^2) and BP(mmHg) will be described at baseline and
      during use of dapagliflozin. Over all questionnaire response rate and rate of response to
      reasons for prescribing dapagliflozin will be described.

      Limitations: Variation in timing and completeness of clinical measures. The patient medical
      records are not collected for research purposes and the diagnostic and procedure coding on
      such data may be recorded incorrectly or not recorded at all, thereby potentially introducing
      measurement error with respect to code-based variables. The centres participating in the
      study, record that a prescription was issued, but not whether it was dispensed from the
      pharmacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a descriptive retrospective observational cohort study using data from Turkish
      patient medical records from 81 different internal medicine and/or endocrinology clinics
      across the whole country.

      The study cohort will include T2D patients who received at least one prescription for
      dapagliflozin for the first time between July 2016 and Aug 2017 and who have been registered
      in that centre for at least 6 months prior to the first dapagliflozin prescription.

      The selection of sites and investigators will be made with an aim to achieve
      representativeness of the way dapagliflozin treated T2D patients are managed across Turkey.
      The National Coordinator will provide advice regarding the proportion of the different types
      of centres (Internal medicine, endocrinology clinics, different types of hospitals,
      geographical distribution) and investigators (different types of specialists) involved in
      dapagliflozin treated T2D patient management. The National Coordinator will also provide
      insight on the national situation regarding dapagliflozin medication prescription
      (reimbursement, public or private insurance). All this information will be used to select
      sites and investigators for the study, resembling as closely as possible, the real-world
      situation.

      Sites will also be evaluated for existence and use of electronic medical records as part of
      feasibility. Data quality of sites will be assessed before initiation visit. The study centre
      database should provide at least 20 patients to the study. In case the study centre, can
      provide more than 20 patients, then patients will be selected randomly by the Contract
      Research Organization. Contract Research Organization will also record total number of
      eligible patients, their age and sex details before performing randomization. The
      randomization process will be performed at the study site after initiation visit by Contract
      Research Organization. The investigator of the centre will enter only selected patients to
      study Case Report Form. The Contract Research Organization will also perform 100% source
      document verification following completion of Case Report Forms by the investigator. All
      centres will be evaluated by Contract Research Organization at initiation visit in terms of
      data quality (Baseline, first visit and second visit data of eligible patients)

      The date of the first prescription for dapagliflozin in patient medical records is the index
      date. Patients will be followed from the index date until the earliest of transfer out date,
      death date or end date of patient records (last date of data collection). Required data
      mentioned in baseline characteristics (section 5.1) will be recorded at index date, first
      visit (2 or 3 or 4 months after index date) and second visit (5 or 6 months after index date)
      of treatment (section 5.2).

      Dataset quality will be assessed by Contract Research Organization at initiation visit. Site
      investigator is responsible for entering data to Case Report Forms. Paper based Case Report
      Form system will be used for this study. Datasets can differ for each hospital and patient's
      records can be electronic and/or printed. The investigator will collect all necessary data
      for each patient retrospectively from the most reliable data source in the clinic. All
      collected data will be verified by the Contract Research Organization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c(%)</measure>
    <time_frame>6 months</time_frame>
    <description>To record the mean change in HbA1C from baseline [ Time Frame: 6 Months ] Changes over time (6 months) in HbA1c(%) value in these patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Total body weight [ Time Frame: 6 Months ]</measure>
    <time_frame>6 months</time_frame>
    <description>The mean changes from mean baselines and at Month 6 in Total body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in BMI [ Time Frame: 6 Months ]</measure>
    <time_frame>6 months</time_frame>
    <description>The mean changes from mean baselines and at Month 6 in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Systolic Blood Pressures</measure>
    <time_frame>6 months</time_frame>
    <description>The mean changes from mean baselines and at Month 6 in Systolic Blood Pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Diastolic Blood Pressures [ Time Frame: 6 Months ]</measure>
    <time_frame>6 months</time_frame>
    <description>The mean changes from mean baselines and at Month 6 in Diastolic Blood Pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rates of dapagliflozin in the first 6 months of treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Discontinuation rates of dapagliflozin in the first 6 months of treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">1683</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forxiga</intervention_name>
    <description>Oral antidiabetics</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study cohort will be selected from patient records of 81 different centres. 1500
        patients are planned to include in this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â¥18 and â¤75 years at index date.

          -  First prescription for dapagliflozin between July 2016 and Aug 2017

          -  Minimum 6 months of registration in the centres at the index date

          -  Established Type 2 diabetes prior to the index date

        Exclusion Criteria:

          -  Patients with Type 1 diabetes

          -  Patients with gestational diabetes

          -  Being included in another interventional clinical trial at between index date and
             enrollment date

          -  Estimated Glomerular Filtration Rate &lt; 30 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SÃ¼leyman ÃzÃ§aylak, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DiyarbakÄ±r Gazi YaÅargil T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KÃ¼rÅat Dal, Assc.ProfDr</last_name>
    <role>Principal Investigator</role>
    <affiliation>KeÃ§iÃ¶ren T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammed Mu DemirpenÃ§e, Spec. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tepecik T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erdal Kan, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsun Medicana Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TuÄba Arkan, Spec. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli Derince T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Canan Ersoy, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uludag University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa Araz, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Gaziantep</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Okan BakÄ±ner, Assc.ProfDr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adana BaÅkent University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramazan Kaya, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mersin Tarsus State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eren GÃ¼rkan, Ast.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mustafa Kemal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hayati Ayakta, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manisa Private Grand Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PÄ±nar SÄ±rmatel, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edirne State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berna Da Ekiz, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MuÄla Private Ä°zan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faruk KÄ±lÄ±nÃ§, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Firat University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ä°brahim Åahin, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>InÃ¶nÃ¼ University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RÄ±fkÄ± ÃÃ§ler, Asc.Prof.Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van 100.YÄ±l University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Semin M FenkÃ§i, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pamukkale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa Aydemir, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afyon State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emre ÃiÃ§ekli, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sivas Medicana Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Åahin DoÄanay, Spec.Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yenimahalle T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ÃzgÃ¼r KeÅkek, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adana City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aytekin OÄuz, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medeniyet University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kerem Sezer, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mersin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>OÄuzhan S Dizdar, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kayseri T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasin KocaÃ¶z, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menemen State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahir Cengiz, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University CerrahpaÅa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NilgÃ¼n G GÄ±ynaÅ, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakan DoÄan, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bozyaka T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erdal GÃ¼ndoÄan, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>BaÄcÄ±lar T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ÃaÄlar KÃ¶seoÄlu, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GÃ¶lbaÅÄ± State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RÄ±fat BozkuÅ, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulus State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murat Medeni, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bornova TÃ¼rkan Ãzilhan State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet ÃelebioÄlu, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>EskiÅehir Private Anadolu Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa ÃalÄ±Åkan, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DÃ¼zce State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Metin GÃ¼Ã§lÃ¼, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bursa YÃ¼ksek Ä°htisas T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ãzcan ÃzbaÄ, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gaziantep T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taner BayraktaroÄlu, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>BÃ¼lent Ecevit University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ÃmÃ¼r Tabak, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanuni Sultan SÃ¼leyman T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erhan Bozkurt, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>EmirdaÄ State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SelÃ§uk Sezikli, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Merzifon State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ersen KarakÄ±lÄ±Ã§, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ãanakkale State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AyÃ§a S Erdem, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ÃskÃ¼dar State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deniz Gezer, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mersin City State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuh BaklacÄ±, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hatay Akademi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabriye Ã KafesÃ§iler, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manisa State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sayid S Zuhur, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Namik Kemal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GÃ¶ktÃ¼rk KÄ±lÄ±nÃ§, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fethiye State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa TimurkaÄan, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ElazÄ±Ä T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ãmit ÃÄ±nkÄ±r, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gaziantep Medicalpark Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Semra Tursun, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denizli Private Tekden Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Memnune S Ulu, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afyon Kocatepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ÃiÄdem B Tuna, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokat State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harun Aysal, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya AtatÃ¼rk State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ZÃ¼leyha Karaca, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murat AkbaÅ, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ä°stanbul EyÃ¼p State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmet Z Åahin, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adana AÅkÄ±m TÃ¼fekÃ§i State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esra Ãil Åen, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ÅiÅli Etfal T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet Ãelik, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Metin SarÄ±kaya, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HacÄ± Bayram, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ãmraniye T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alparslan K Tuzcu, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dicle University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derun T ErtuÄrul, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KeÃ§iÃ¶ren T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ä°lhan Yetkin, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet ÃoÅkun, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DiyarbakÄ±r Gazi YaÅargil T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevser OnbaÅÄ±, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>T.C. DumlupÄ±nar Ãniversitesi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet A Eren, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harran University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RÄ±fat Emral, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramazan Gen, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mersin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esra AtaoÄlu, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haseki T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BarÄ±Å AkÄ±ncÄ±, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz EylÃ¼l University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramazan SarÄ±, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akdeniz University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emre BozkÄ±rlÄ±, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adana BaÅkent University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kubilay KarÅÄ±daÄ, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Istanbul Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamer Tetiker, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ãukurova University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Levent KebapÃ§Ä±lar, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SelÃ§uk University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>YÄ±ldÄ±z Okuturlar, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>BakÄ±rkÃ¶y Dr.Sadi Konuk T&amp;R Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enver ÅÃ¼krÃ¼ GÃ¶ncÃ¼oÄlu, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Nazif BaÄrÄ±aÃ§Ä±k KadÄ±kÃ¶y Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BengÃ¼r TaÅkÄ±ran, Spec.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>EskiÅehir Yunus Emre State Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ä°nan AnaforoÄlu, Asc.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trabzon Medicalpark Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KeÃ§iÃ¶ren Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Dapagliflozin</keyword>
  <keyword>Endocrinology</keyword>
  <keyword>Internal diseases</keyword>
  <keyword>Type II diabetes mellitus</keyword>
  <keyword>HbA1c</keyword>
  <keyword>BMI</keyword>
  <keyword>BP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

